Although prostate cancer can metastasize to any part of the body, laryngeal cartilage metastasis is extremely rare and few cases have been published so far. Here we present the case of a 65-year-old male patient, recently diagnosed with prostate adenocarcinoma, referred for staging with 68 Ga-PSMA PET/CT. He was found to have extensive skeletal metastasis along with cartilage metastasis involving both thyroid and cricoid cartilages.
Few studies have been performed to evaluate the p53 protein expression in gallbladder carcinoma and its relationship to histopathological grade of the tumor. Based on these facts the aim of our study was to assess the p53 overexpression in correlation to the grade of tumor. Material and Methods: 80 cases of histologically proven gall bladder carcinoma were included in the study.p53 immunostaining was done and score was calculated. Results: It was observed that out of 80 cases of gall bladder malignancy, 30(37.5%) cases were p53 positive and 50(62.5%) were p53 negative. There was statistically significant difference between the histological grade of p53 positive and p53 negative adenocarcinomas with significantly higher number of patients of p53 overexpression presenting with poorly differentiated adenocarcinomas. Conclusion: p53 overexpression has inverse relationship with the grade of the tumor.
Uptake of
68
Ga-prostate-specific membrane antigen (PSMA) in various nonprostatic tumors is well documented in the literature. We present a case of a gastrointestinal stromal tumor, incidentally detected on
68
Ga-PSMA positron emission tomography/computed tomography imaging in a patient who underwent imaging for a suspected recurrence of carcinoma prostate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.